Peripheral stem cell mobilization and engraftment in patients over age 60.
Data from 225 multiple myeloma (MM) patients, undergoing peripheral stem cell (PBSC) mobilization with high-dose cyclophosphamide and hematopoietic growth factors, were analyzed for median CD34+ cell count and median time to post-transplant neutrophil (ANC > 500/microliters) and platelet (> 50,000/microliters) recovery according to age groups (20-49, 50-59 and > or = 60 years) and duration of prior therapy (< or = 12, 13-24, or > 24 months). Fifty-seven of the 225 patients were > or = 60 years. No difference in either the median number of CD34+ cells collected or time to engraftment occurred between age groups, when adjusted for duration of prior therapy. These data support the concept that autotransplants can be performed safely in patients > or = 60 years and that these patients should not be excluded from the most effective treatment modalities.